Open Nav


Series A Investment

  • Date:Thursday, October 18
  • Time:11:00 AM - 11:15 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:VERAVAS™ is a diagnostic company with a research facility in Oakdale, MN that will transform the practice of laboratory medicine through novel, breakthrough sample prep technologies. These technologies will address some of the most pressing challenges facing traditional laboratory testing methods while at the same time enhancing the quality of care. Our novel biomarker diagnostic platform VERAPREP™ can quickly commercialize low abundance biomarkers to meet unmet clinical needs, reduce the effects of troublesome sample interferences, and can dramatically reduce the cost of diagnostic testing.
  • Company To be launched early October 2018
  • Company HQ City:Charleston
  • Company HQ Country:United States
  • Company HQ State:South Carolina       
  • CEO/Top Company Official:John Forrest
  • Year Founded:2017
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development :VERAPREP
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :10
  • Additional Information/Comments:VERAPrep™ is based on a patent pending technology that selectively captures, cleans, and concentrates multiple biomarkers prior to a test. VERAPrep™ is unique because it pretreats human samples to (i) remove many complicating factors that can interfere with test results, (ii) capture low abundance biomarkers and (iii) concentrate the targets to create large improvements in sensitivity over existing methods. Our experienced executive team includes world renown scientists including an industry subject matter expert in assay design and solid phase chemistry, Josh Soldo, and Carmen Wiley, PhD, Board Certified Clinical Chemist, Mayo Clinic trained, former Scientific Director of a US national reference lab and President-elect of America Association for Clinical Chemistry.
  • Previous and Current Investors:Angel Investors
  • Size of Last Investment Round:$1.27 M
  • Total Amount Raised to Date, In All Rounds:$1.27 M
John Forrest